89Zr-度伐利尤单抗PET/CT在晚期非小细胞肺癌中的PD-L1显像研究
该研究纳入13例拟接受二线免疫治疗的晚期NSCLC患者,分别行仅示踪剂剂量和预注射750 mg度伐利尤单抗后的89Zr-度伐利尤单抗PET/CT显像,评估安全性、生物分布及肿瘤摄取与PD-L1表达和临床疗效的关系。结果显示无示踪剂相关不良事件,仅示踪剂剂量显像可显示更多肿瘤病灶(25% vs 13.5%),肿瘤摄取在治疗应答或疾病稳定患者中高于疾病进展患者但差异无统计学意义(中位SUVpeak 4.9 vs 2.4;P=0.06)。
要点
- 89Zr-度伐利尤单抗PET/CT安全,无示踪剂相关不良事件。
- 仅示踪剂剂量显像较共注射显像可显示更多肿瘤病灶(25% vs 13.5%)。
- 肿瘤摄取与疗效差异无统计学意义,与PD-L1免疫组化无显著相关。
核心结论
- 89Zr-度伐利尤单抗安全,无示踪剂相关不良事件,仅示踪剂剂量显像可显示更多肿瘤病灶。
- 肿瘤摄取在度伐利尤单抗治疗应答患者中较高,但与肿瘤PD-L1免疫组化无显著相关。
研究设计与样本
- 纳入适合二线免疫治疗的NSCLC患者,接受两次89Zr-度伐利尤单抗注射:一次仅示踪剂剂量,一次预注射750 mg度伐利尤单抗后注射示踪剂。
- 示踪剂注射后最多行4次PET/CT扫描,随后每2周接受750 mg度伐利尤单抗治疗。
- 共纳入13例患者,其中10例完成所有计划PET扫描。
主要发现
- 未观察到示踪剂相关不良事件,所有患者均开始度伐利尤单抗治疗。
- 生物分布分析显示89Zr-度伐利尤单抗在血池、肝脏和脾脏中蓄积。
- 系列显像显示注射后120小时图像采集提供最佳肿瘤与血池比值。
- 仅示踪剂剂量显像较共注射显像可显示更多肿瘤病灶(25% vs 13.5%)。
- 肿瘤摄取存在患者内(SUVpeak范围0.2-15.1)和患者间异质性。
关键数值与推荐
- 根据RECIST 1.1,治疗应答或疾病稳定患者肿瘤摄取高于疾病进展患者,但差异无统计学意义(中位SUVpeak 4.9 vs 2.4;P=0.06)。
- SUVpeak与联合肿瘤和免疫细胞PD-L1评分相关性优于肿瘤细胞PD-L1表达,但均无统计学意义(P=0.06和P=0.93)。
临床怎么用
- 89Zr-度伐利尤单抗PET/CT显像安全可行,仅示踪剂剂量方案可显示更多肿瘤病灶。
- 该显像可能有助于评估肿瘤PD-L1表达异质性,但预测疗效和PD-L1免疫组化相关性的价值尚需进一步验证。
局限性
- 样本量小(13例),仅10例完成所有计划PET扫描。
- 肿瘤摄取与疗效及PD-L1表达的相关性均未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Better biomarkers are needed to predict treatment outcome in non-small cell lung cancer (NSCLC) patients treated with anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors. PD-L1 immunohistochemistry has limited predictive value, possibly because of tumor heterogeneity of PD-L1 expression. Noninvasive PD-L1 imaging using 89Zr-durvalumab might better reflect tumor PD-L1 expression. Methods: NSCLC patients eligible for second-line immunotherapy were enrolled. Patients received 2 injections of 89Zr-durvalumab: one without a preceding dose of unlabeled durvalumab (tracer dose only) and one with a preceding dose of 750 mg of durvalumab, directly before tracer injection. Up to 4 PET/CT scans were obtained after tracer injection. After imaging acquisition, patients were treated with 750 mg of durvalumab every 2 wk. Tracer biodistribution and tumor uptake were visually assessed and quantified as SUV, and both imaging acquisitions were compared. Tumor tracer uptake was correlated with PD-L1 expression and clinical outcome, defined as response to durvalumab treatment. Results: Thirteen patients were included, and 10 completed all scheduled PET scans. No tracer-related adverse events were observed, and all patients started durvalumab treatment. Biodistribution analysis showed 89Zr-durvalumab accumulation in the blood pool, liver, and spleen. Serial imaging showed that image acquisition 120 h after injection delivered the best tumor-to-blood pool ratio. Most tumor lesions were visualized with the tracer dose only versus the coinjection imaging acquisition (25% vs. 13.5% of all lesions). Uptake heterogeneity was observed within (SUVpeak range, 0.2-15.1) and between patients. Tumor uptake was higher in patients with treatment response or stable disease than in patients with disease progression according to RECIST 1.1. However, this difference was not statistically significant (median SUVpeak, 4.9 vs. 2.4; P = 0.06). SUVpeak correlated better with the combined tumor and immune cell PD-L1 score than with PD-L1 expression on tumor cells, although neither was statistically significant (P = 0.06 and P = 0.93, respectively). Conclusion:89Zr-durvalumab was safe, without any tracer-related adverse events, and more tumor lesions were visualized using the tracer dose-only imaging acquisition. 89Zr-durvalumab tumor uptake was higher in patients with a response to durvalumab treatment but did not correlate with tumor PD-L1 immunohistochemistry.
引用
- Smit J, Borm FJ, Niemeijer AN, et al. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2021. PMID: 34385342. doi:10.2967/jnumed.121.262473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。